Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators

Biomaterials

Volumn 17, Issue 16, 1996, Pages 1575-1581

  Vittaz, Michaëlla ^a   Bazile, Didier ^b   Spenlehauer, Gilles ^b   Verrecchia, Thierry ^b   Veillard, Michel ^b   Puisieux, Francis ^a   Labarre, Denis ^a  

^a UNIV PARIS SUD   (France)

^b SANOFI   (France)

Author keywords

Complement system; Drug delivery; Nanoparticles; PEO surface density; Poly(lactic acid coethylene oxide)

Indexed keywords

CELLS; HEMODYNAMICS; NANOSTRUCTURED MATERIALS; POLYETHYLENE OXIDES; PROTEINS; SURFACE PROPERTIES;

COMPLEMENT ACTIVATORS; MONONUCLEAR PHAGOCYTES SYSTEM; NANOPARTICLES; NANOPARTICULATE DRUG CARRIERS; OPSONIN; OPSONIZATION; PATHOGENIC AGENTS; PHAGOCYTOSIS; POLYLACTIC ACID COETHYLENE OXIDE;

DRUG THERAPY;

NANOPARTICLE; OPSONIN; POLYLACTIC ACID;

ARTICLE; CIRCULATION TIME; COMPLEMENT ACTIVATION; DENSITY; DRUG DELIVERY SYSTEM; HUMAN; MACROPHAGE; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0030209082     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/0142-9612(95)00322-3     Document Type: Article

References (28)

1. 1 Vert M, Li SM, Spenlehauer G, Guérin P. Bioresorbability and biocompatibility of aliphatic polyesters. J Mater Sci: Mater in Med 1992; 3: 432-146.
2. 2 Puisieux F, Barratt G, Courraze G, Couvreur P, Devissaguet JP, Dubernet C, Fattal E, Fessi H, Vauthier C, Benita S. Polymeric micro-and nanoparticles as drug carriers. In: Duraitriu S, ed. Polymeric Biomaterials. New York: M. Dekker, 1994; 749-794.
3. 3 Artursson P, Sjöholm I. Effect of opsonins on the macrophage uptake of polyacrylstarch microparticles. Int J Pharm 1986; 32: 165-170.
4. 4 Borchard G, Kreuter J, Interaction of serum components with poly(methyl methacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. J Drug Target 1993; 1: 15-19.
5. 5 Kinoshita T. Biology of complement: the overture. Immunology Today 1991; 12: 291-295.
6. 6 Kazatchkine MD, Nydegger UE. The human alternative complement pathway: Biology and immunopathology of activation and regulation. Prog Allergy 1982; 30: 193-234.
7. 7 Law SK, Lichtenberg NA, Levine RP. Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol 1979; 123: 1388-1394.
8. 8 Nilsson UR, Storm KE, Elwing H, Nilsson B. Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. Mol Immunol 1993; 30: 211-219.
9. 9 Jahns G, Haeffher-Cavaillon N, Nydegger UE, Kazatchkine MD. Complement activation and cytokine production as consequences of immunological bioincompatibility of extracorporeal circuits. Clin Mater 1993; 14: 303-336.
10. 10 Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunology Today 1991; 12: 322-326.
11. 11 Illum L, Davis SS, Müller RH, Mak E, West P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer polyoxamine 908, Life Sci 1987; 40: 367-374.
12. 14C-poly(methyl methacrylate) nanoparticles. J Microencapsul 1992; 9: 19-28.
13. 13 Wassef NM, Matyas GR, Alving GR. Complement-dependent phagocytosis of liposomes by macrophages: suppressive effects of "stealth" lipids. Biochem Biophys Res Commun 1991; 176: 866-874.
14. 14 Verrecchia T, Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, Veillard M, Non-stealth (poly (lactic acid/albumin)) and stealth (poly (lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J Controlled Release 1995; 36: 49-61.
15. 15 Bazile D, Michalon JP, Prud'homme C, Spenlehauer G, Veillard M. Nanoparticules ayant un temps de capture par le système réticulo-endothélial allongé. French Patent 08,041, 1991.
16. 16 Bazile D, Prud'homme C, Bassoullet MT, Mariard M, Spenlehauer G, Veillard M, Stealth Me.PEG-PLA nanoparticles avoid uptake by the niononuclear phagocytes system. J Pharm Sci 1995; 84: 493-498.
17. 17 Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600-1603.
18. 18 Baleux B. Dosage colorimétrique d'agents de surface non ioniques polyoxyéthylène à l'aide d'une solution iodo-iodurée, CR Acad Sci Paris 1972; 274: C1617-C1619.
19. 19 Sims GEC, Snape TJA. Method for the estimation of polyethylene glycol in plasma protein fractions. Anal Biochem 1980; 107: 60-63.
20. 20 Mayer MM. Complement and complement fixation. In: Kabat EA, Mayer MM, eds. Experimental Immunochemistry, 2nd edn. Springfield, IL, USA: Thomas, 1961; 133-156.
21. 21 Kazatchkine MD, Hauptmann G, Nydegger UE. Techniques du Complément. INSERM, Paris, 1986; 22-33.
22. 22 Labarre D, Montdargent B, Carreno MP, Maillet F. Strategy for in vitro evaluation of the interactions between biomaterials and complement system. J Appl Biomater 1993; 4: 231-240.
23. 23 Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994; 11: 402-406.
24. 24 Ward CA, Koheil A, Johnson WR, Madras PN. Reduction in complement activation from biomaterials by removal of air nuclei from the surface roughness. J Biomed Mater Res 1984; 18: 255-269.
25. 25 Jeon SI, Lee JH, Andrade JD, De Gennes PG. Protein-Surface interactions in the presence of polyethylene oxide; 1. Simplified theory. J Colloid Interf Sci 1991; 142: 149-158.
26. 26 Jeon SI, Andrade JD, Protein-Surface interactions in the presence of polyethylene oxide; 2. Effect of protein size. J Colloid Interf Sci 1991; 142: 159-166.
27. 27 Chaikof EL, Merrill EW, Callow AD, Connolly RJ, Verdon SL, Ramberg K. PEO enhancement of platelet deposition, fibrinogen deposition and complement C3 activation. J Biomed Mater Res 1992; 26: 1163-1168.
28. 28 Toufik J, Carreno MP, Jozefowicz M, Labarre D. Activation of the complement system by polysaccharidic surfaces bearing carboxymethyl, carboxymethylbenzylamide and carboxymethylbenzylamide sulphonate groups. Biomaterials 1995; 16: 993-1002.